A Phase II Study Of PS-341 [bortezomib] (NSC 681239) In Patients With Untreated Or Relapsed Mantle Cell Lymphoma

Trial Profile

A Phase II Study Of PS-341 [bortezomib] (NSC 681239) In Patients With Untreated Or Relapsed Mantle Cell Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Mar 2010 Actual end date (1 Dec 2009) added as reproted by ClinicalTrials.gov record.
    • 11 Sep 2009 Planned end date (28 Jul 2004) added as reported by National Cancer Institute of Canada.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top